Uncategorized

Needham analysts, who were surprised by the bargain for Paragon 28, said Zimmer may not be done spending.

States and providers regained access to a key healthcare payments portal late Tuesday amid widespread backlash over the Trump administration’s decision to halt federal aid.

The layoffs follow an announcement in early January that I-Mab will re-prioritize resources to focus on advancing a CLDN18.2 and 4-1BB bispecific antibody for gastric cancers.

Although experts predict payers, providers and health technology companies will grapple with uncertainty in a second Trump administration, some hope that years-long headwinds could begin reversing course in 2025.

The move is part of a strategic restructuring aimed at getting azenosertib to the market for patients with gynecological malignancies.

The approval continues the trend of GLP-1s expanding to indications outside of diabetes and weight loss.

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an overlapping patient population.

Site-neutral payment policy is a distraction from the underlying causes of high healthcare costs and places providers at risk, argues Ascension’s chief health outcomes officer.

La zona habitable alrededor de una estrella es la franja orbital en la cual el calor que llega de la estrella es el justo para permitir la existencia de agua líquida en la superficie de los posibles planetas allí situados. El agua es uno de los ingredientes clave para la vida tal como …

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the second round of the IRA drug price negotiation program, even as the pharma challenges the program.